JP2016516050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516050A5 JP2016516050A5 JP2016502973A JP2016502973A JP2016516050A5 JP 2016516050 A5 JP2016516050 A5 JP 2016516050A5 JP 2016502973 A JP2016502973 A JP 2016502973A JP 2016502973 A JP2016502973 A JP 2016502973A JP 2016516050 A5 JP2016516050 A5 JP 2016516050A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- methyl
- oxopyrrolidin
- methylnon
- oxopyrrolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 128
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 120
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 75
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 50
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 claims description 44
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- -1 C 1 -C 3 alkoxy Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000005711 Benzoic acid Substances 0.000 claims description 17
- 235000010233 benzoic acid Nutrition 0.000 claims description 17
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 claims description 16
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 16
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- 125000004419 alkynylene group Chemical group 0.000 claims description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 6
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 6
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 6
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 4
- LSHMGTXEUMQTLQ-DMBFJYOSSA-N 7-[(2r)-2-[(e,3r)-3-hydroxy-3-(1-pent-2-ynylcyclobutyl)prop-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound CCC#CCC1([C@H](O)\C=C\[C@@H]2N(C(=O)CC2)CCCCCCC(O)=O)CCC1 LSHMGTXEUMQTLQ-DMBFJYOSSA-N 0.000 claims description 2
- PZTUDMCYRNFKGN-GMIBQGTOSA-N 7-[(2r)-2-[(e,3r)-3-hydroxy-3-(1-pent-2-ynylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound CCC#CCC1([C@H](O)\C=C\[C@@H]2N(C(=O)CC2)CCCCCCC(O)=O)CC1 PZTUDMCYRNFKGN-GMIBQGTOSA-N 0.000 claims description 2
- 206010065687 Bone loss Diseases 0.000 claims description 2
- 206010017076 Fracture Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000005622 butynylene group Chemical group 0.000 claims description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 210000002805 bone matrix Anatomy 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793736P | 2013-03-15 | 2013-03-15 | |
| US61/793,736 | 2013-03-15 | ||
| PCT/US2014/029057 WO2014144584A2 (en) | 2013-03-15 | 2014-03-14 | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109178A Division JP6352497B2 (ja) | 2013-03-15 | 2017-06-01 | Ｅｐ４媒介性の疾病及び病態の治療に使用するためのｅｐ４受容体選択性アゴニストとしてのラクタム化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516050A JP2016516050A (ja) | 2016-06-02 |
| JP2016516050A5 true JP2016516050A5 (enExample) | 2017-04-20 |
| JP6317807B2 JP6317807B2 (ja) | 2018-04-25 |
Family
ID=50897877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502973A Active JP6317807B2 (ja) | 2013-03-15 | 2014-03-14 | Ｅｐ４媒介性の疾病及び病態の治療に使用するためのｅｐ４受容体選択性アゴニストとしてのラクタム化合物 |
| JP2017109178A Expired - Fee Related JP6352497B2 (ja) | 2013-03-15 | 2017-06-01 | Ｅｐ４媒介性の疾病及び病態の治療に使用するためのｅｐ４受容体選択性アゴニストとしてのラクタム化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109178A Expired - Fee Related JP6352497B2 (ja) | 2013-03-15 | 2017-06-01 | Ｅｐ４媒介性の疾病及び病態の治療に使用するためのｅｐ４受容体選択性アゴニストとしてのラクタム化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9688627B2 (enExample) |
| EP (2) | EP3235817B1 (enExample) |
| JP (2) | JP6317807B2 (enExample) |
| KR (1) | KR20150130326A (enExample) |
| CN (1) | CN105143217A (enExample) |
| AU (1) | AU2014228973B2 (enExample) |
| BR (1) | BR112015023080A2 (enExample) |
| CA (1) | CA2906134A1 (enExample) |
| DK (1) | DK2989098T3 (enExample) |
| EA (1) | EA201591793A1 (enExample) |
| ES (1) | ES2635635T3 (enExample) |
| IL (2) | IL240988A (enExample) |
| PH (1) | PH12015502165A1 (enExample) |
| PT (1) | PT2989098T (enExample) |
| SG (1) | SG11201507470WA (enExample) |
| WO (1) | WO2014144584A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2875022B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| CN105392505A (zh) | 2013-07-19 | 2016-03-09 | 开曼化学股份有限公司 | 用于促进骨生长的方法、系统和组合物 |
| CN107365329B (zh) * | 2016-05-12 | 2019-02-01 | 华东师范大学 | 一种3-甲基-2-氧代-5-庚炔基磷酸二甲酯的制备方法 |
| PL3733665T3 (pl) | 2017-12-25 | 2023-02-06 | Asahi Kasei Pharma Corporation | Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| CA1085859A (en) | 1975-06-27 | 1980-09-16 | Wilhelm Bartmann | Pyrrolidones and process for their manufacture |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4268522A (en) | 1976-06-14 | 1981-05-19 | Pfizer Inc. | 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| AP2002002555A0 (en) | 1999-12-22 | 2002-06-30 | Pfizer Prod Inc | EP4 Receptor selective agonists in the treatment of osteoporosis. |
| US20010056060A1 (en) | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| EA200300379A1 (ru) * | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| JP2004521954A (ja) | 2001-07-16 | 2004-07-22 | エフ．ホフマン−ラ ロシュ アーゲー | Ｅｐ４受容体作用薬としてのプロスタグランジン類似体 |
| PL215425B1 (pl) | 2001-07-16 | 2013-12-31 | Ono Pharmaceutical Co | Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie |
| JP4273407B2 (ja) | 2001-07-23 | 2009-06-03 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 |
| AU2002340282B2 (en) | 2001-10-23 | 2007-08-09 | Merck Serono Sa | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors |
| WO2003047417A2 (en) | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
| AU2002346562A1 (en) | 2001-12-03 | 2003-06-17 | Merck & Co., Inc. | Method for treating ocular hypertension |
| AU2003211574A1 (en) | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| ATE336247T1 (de) | 2002-03-18 | 2006-09-15 | Pfizer Prod Inc | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten |
| EP1490055A1 (en) | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2003237520B2 (en) * | 2002-06-10 | 2009-01-08 | Laboratoires Serono Sa | Gamma lactams as prostaglandin agonists and use thereof |
| WO2004037786A2 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
| WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| JP4662926B2 (ja) * | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| EP1782829A1 (en) | 2004-08-10 | 2007-05-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| US7858610B2 (en) | 2004-08-10 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
| JP5040650B2 (ja) * | 2005-06-03 | 2012-10-03 | 小野薬品工業株式会社 | 神経再生および／または保護剤 |
| US20070232660A1 (en) | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| CN101686985A (zh) | 2007-05-08 | 2010-03-31 | 国立大学法人浜松医科大学 | 含有ep4激动剂的细胞毒性t细胞的活化剂 |
| EP2215084B1 (en) | 2007-10-23 | 2016-09-28 | Allergan, Inc. | Therapeutic substituted lactams |
| WO2011003058A1 (en) * | 2009-07-03 | 2011-01-06 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
| EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| US20120283293A1 (en) | 2011-05-06 | 2012-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation |
| US9682065B2 (en) | 2011-08-02 | 2017-06-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| EP2875022B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
-
2014
- 2014-03-14 PT PT147291066T patent/PT2989098T/pt unknown
- 2014-03-14 JP JP2016502973A patent/JP6317807B2/ja active Active
- 2014-03-14 EP EP17169751.9A patent/EP3235817B1/en not_active Not-in-force
- 2014-03-14 BR BR112015023080A patent/BR112015023080A2/pt not_active IP Right Cessation
- 2014-03-14 DK DK14729106.6T patent/DK2989098T3/en active
- 2014-03-14 WO PCT/US2014/029057 patent/WO2014144584A2/en not_active Ceased
- 2014-03-14 SG SG11201507470WA patent/SG11201507470WA/en unknown
- 2014-03-14 AU AU2014228973A patent/AU2014228973B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157026225A patent/KR20150130326A/ko not_active Withdrawn
- 2014-03-14 CA CA2906134A patent/CA2906134A1/en active Pending
- 2014-03-14 CN CN201480015554.7A patent/CN105143217A/zh active Pending
- 2014-03-14 ES ES14729106.6T patent/ES2635635T3/es active Active
- 2014-03-14 US US14/775,427 patent/US9688627B2/en active Active
- 2014-03-14 EP EP14729106.6A patent/EP2989098B1/en active Active
- 2014-03-14 EA EA201591793A patent/EA201591793A1/ru unknown
-
2015
- 2015-09-01 IL IL240988A patent/IL240988A/en active IP Right Grant
- 2015-09-15 PH PH12015502165A patent/PH12015502165A1/en unknown
-
2017
- 2017-01-12 IL IL250077A patent/IL250077A0/en unknown
- 2017-06-01 JP JP2017109178A patent/JP6352497B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522623A5 (enExample) | ||
| HRP20130143T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| RU2010146485A (ru) | Новые лиганды эстрогеновых рецепторов | |
| JP2016527006A5 (enExample) | ||
| JP2005536475A5 (enExample) | ||
| HRP20150082T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2006515604A5 (enExample) | ||
| HRP20170045T1 (hr) | Difluorlaktamski spojevi kao selektivni agonisti ep4 receptora za uporabu za liječenje bolesti i stanja posredovanih s ep4 receptorom | |
| JP2014507443A5 (enExample) | ||
| JP2009506039A5 (enExample) | ||
| JP2014525426A5 (enExample) | ||
| WO2015009991A2 (en) | Methods, systems, and compositions for promoting bone growth | |
| JP2008523041A5 (enExample) | ||
| WO2004103279A3 (en) | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | |
| JP2017522374A5 (enExample) | ||
| JP2016505619A5 (enExample) | ||
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| JP2013507336A5 (enExample) | ||
| RU2017134973A (ru) | Бутиролактоны в качестве гербицидов | |
| HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
| EP2682387A3 (en) | C7-fluoro substituted tetracycline compounds | |
| JP2014502979A5 (enExample) | ||
| RU2019123404A (ru) | Производное пиримидина | |
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| JP2017511378A5 (enExample) |